Immuno-oncology & Oncology

Cancer immunotherapy is one of the most promising anti-cancer therapeutic breakthroughs in recent years. Biocytogen provides immuno-oncology and preclinical oncology services, offering the highest quality and the most comprehensive collection of genetically humanized immune-checkpoint mouse models to accelerate the discovery and development of therapeutics. In addition to immuno-oncology services, Biocytogen provides robust human immune cell-engrafted mouse models. Our CDX and PDX mouse models can be used to support preclinical efficacy investigation of immuno-oncology and oncology drugs. Our preclinical oncology services can help drug discovery via multiple modalities. 

Humanized Immune-checkpoint Mice

Mice with knocked-in human targets, paired with genetically modified syngeneic mouse cancer cell lines, as powerful in vivo efficacy models.

Learn More

Humanized CD3ε model

Novel humanized CD3ε mouse model is a useful tool for in vivo efficacy study of CD3– mediated therapy, especially anti-CD3 bispecific antibodies.

Learn More

CAR-T Efficacy Evaluation

Severely immune-deficient B-NDG mice implated with hematologic and solid tumor cells for CAR-T efficacy tests.

Learn More

Human Immune System Engraftment

B-NDG mice engrafted with human immune cells (PBMCs and hHSCs) are powerful tools to examine therapeutic effects of test agents on human immune system.

Learn More

CDX Model

B-NDG mice implanted with human cancer cell lines are usefulmodels for evaluating in vivo efficacy of chemotherapy, radiotherapy and targeted therapy.

Learn More

PDX Model

Patient-derived tumors xenografted on B-NDG mice present more physiologically relevant models with tumor microenvironments more closely resembling those in patients.

Learn More